ACADIA PHARMACEUTICALS INC. (ACAD) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $16.00K; Additional Paid in Capital, Common StockUSD $3.09B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-958.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $16.00K; Additional Paid in Capital, Common StockUSD $3.06B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-563.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $16.00K; Additional Paid in Capital, Common StockUSD $3.04B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.45M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $16.00K; Additional Paid in Capital, Common StockUSD $3.00B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $989.00K.
ACADIA PHARMACEUTICALS INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $16.00K | $3.09B | $-958.00K | $-1.78B | $1.31B | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $16.00K | $3.06B | $-563.00K | $-1.81B | $1.25B | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $16.00K | $3.04B | $1.45M | $-1.81B | $1.23B | 12 month · $52.56M | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $16.00K | $3.00B | $989.00K | $-2.09B | $917.27M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $16.00K | $2.98B | $406.00K | $-2.16B | $822.38M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $16.00K | $2.95B | $437.00K | $-2.19B | $765.24M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $16.00K | $2.94B | $292.00K | $-2.20B | $732.79M | 12 month · $67.47M | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $16.00K | $2.92B | $858.00K | $-2.35B | $577.18M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $16.00K | $2.90B | $-339.00K | $-2.38B | $516.70M | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $16.00K | $2.88B | $-229.00K | $-2.41B | $464.04M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $16.00K | $2.86B | $24.00K | $-2.43B | $431.75M | 12 month · $66.50M | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $16.00K | $2.84B | $-319.00K | $-2.48B | $362.17M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $16.00K | $2.81B | $-535.00K | $-2.41B | $395.79M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $16.00K | $2.79B | $-220.00K | $-2.41B | $374.26M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $16.00K | $2.77B | $-975.00K | $-2.37B | $400.41M | 12 month · $68.08M | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $16.00K | $2.75B | $-1.36M | $-2.33B | $425.69M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $16.00K | $2.74B | $-843.00K | $-2.30B | $434.85M | (m) | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $16.00K | $2.71B | $-612.00K | $-2.27B | $444.80M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $16.00K | $2.69B | $-192.00K | $-2.15B | $540.89M | 12 month · $63.82M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $16.00K | $2.68B | $-1.00K | $-2.11B | $566.96M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $16.00K | $2.66B | $38.00K | $-2.10B | $564.84M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $16.00K | $2.63B | $34.00K | $-2.05B | $581.61M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $16.00K | $2.61B | $36.00K | $-1.99B | $627.01M | 12 month · $84.44M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $16.00K | $2.57B | $509.00K | $-1.92B | $654.87M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $15.00K | $2.50B | $1.48M | $-1.83B | $663.01M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $15.00K | $2.43B | $1.52M | $-1.79B | $638.38M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $15.00K | $2.40B | $297.00K | $-1.70B | $699.13M | 12 month · $82.80M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $15.00K | $2.34B | $420.00K | $-1.65B | $689.29M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $14.00K | $2.00B | $554.00K | $-1.61B | $388.91M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $14.00K | $1.97B | $207.00K | $-1.55B | $418.36M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $14.00K | $1.95B | $-372.00K | $-1.47B | $479.08M | 12 month · $82.31M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $12.00K | $1.63B | $-314.00K | $-1.40B | $223.44M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $12.00K | $1.61B | $-500.00K | $-1.34B | $264.72M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $12.00K | $1.58B | $-699.00K | $-1.28B | $304.17M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $12.00K | $1.56B | $-399.00K | $-1.22B | $335.29M | 12 month · $75.88M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $12.00K | $1.53B | $-73.00K | $-1.15B | $377.33M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $12.00K | $1.50B | $-97.00K | $-1.09B | $415.14M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $12.00K | (m) | $94.00K | $-1.02B | $457.52M | (m) | $1.48B | (m) | (m) |
| 2016-12-31 | (m) | $12.00K | $1.45B | $106.00K | $-933.98M | $518.41M | 12 month · $56.13M | $1.45B | (m) | (m) |
| 2016-09-30 | (m) | $12.00K | (m) | $533.00K | $-855.28M | $578.06M | (m) | $1.43B | (m) | (m) |
| 2016-06-30 | (m) | $11.00K | (m) | $206.00K | $-783.67M | $408.81M | (m) | $1.19B | (m) | (m) |
| 2016-03-31 | (m) | $11.00K | (m) | $316.00K | $-712.35M | $445.25M | (m) | $1.16B | (m) | (m) |
| 2015-12-31 | (m) | $10.00K | (m) | $11.00K | $-662.59M | $199.76M | 12 month · $40.19M | $862.33M | 12 month · $292.00K | (m) |
| 2015-09-30 | (m) | $10.00K | (m) | $45.00K | $-616.80M | $227.35M | (m) | $844.09M | (m) | (m) |
| 2015-06-30 | (m) | $10.00K | (m) | $11.00K | $-577.90M | $255.82M | (m) | $833.70M | (m) | (m) |
| 2015-03-31 | (m) | $10.00K | (m) | $4.00K | $-538.52M | $285.09M | (m) | $823.60M | (m) | (m) |
| 2014-12-31 | (m) | $10.00K | (m) | $-9.00K | $-498.14M | $309.49M | 12 month · $16.04M | $807.63M | (m) | (m) |
| 2014-09-30 | (m) | $10.00K | (m) | $77.00K | $-469.78M | $330.49M | (m) | $800.18M | (m) | (m) |
| 2014-06-30 | (m) | $10.00K | (m) | $94.00K | $-444.99M | $350.11M | (m) | $795.00M | (m) | (m) |
| 2014-03-31 | (m) | $10.00K | (m) | (m) | $-423.50M | $365.46M | (m) | $788.95M | (m) | (m) |
| 2013-12-31 | (m) | $9.00K | (m) | $48.00K | $-405.67M | $182.13M | 12 month · $5.71M | $587.74M | (m) | (m) |
| 2013-09-30 | (m) | $9.00K | (m) | $84.00K | $-393.62M | $180.75M | (m) | $574.28M | (m) | (m) |
| 2013-06-30 | (m) | $8.00K | (m) | $-26.00K | $-382.92M | $181.47M | (m) | $564.42M | (m) | (m) |
| 2013-03-31 | (m) | $7.00K | (m) | $15.00K | $-373.84M | $79.66M | (m) | $453.48M | (m) | (m) |
| 2012-12-31 | (m) | $7.00K | (m) | $4.00K | $-367.72M | $84.98M | 12 month · $1.93M | $452.69M | (m) | (m) |
| 2012-09-30 | (m) | $6.00K | (m) | $4.00K | $-360.91M | $17.66M | (m) | $378.56M | (m) | (m) |
| 2012-06-30 | (m) | $5.00K | (m) | $3.00K | $-358.51M | $12.71M | (m) | $371.21M | (m) | (m) |
| 2012-03-31 | (m) | $5.00K | (m) | $6.00K | $-353.09M | $17.59M | (m) | $370.66M | (m) | (m) |
| 2011-12-31 | (m) | $5.00K | (m) | $9.00K | $-346.87M | $23.36M | 12 month · $1.60M | $370.22M | (m) | (m) |
| 2011-09-30 | (m) | $5.00K | (m) | $6.00K | $-341.57M | $28.14M | (m) | $369.70M | (m) | (m) |
| 2011-06-30 | (m) | $5.00K | (m) | $10.00K | $-336.50M | $32.82M | (m) | $369.30M | (m) | (m) |
| 2010-12-31 | (m) | $4.00K | (m) | $512.00K | $-324.11M | $29.69M | 12 month · $1.58M | $353.28M | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | $12.11M | 12 month · $2.13M | (m) | (m) | 12 month · $509.00K |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $52.99M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |